Jennison Associates
ELDN icon

Jennison Associates’s Eledon Pharmaceuticals ELDN Stock Holding History

Jennison Associates’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-970
Closed -$2.38M – 731
2014
Q3 		$2.38M Buy
+970
New +$2.76M ﹤0.01% 566

Other funds holding ELDN

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates's ELDN Position: Q4 2014 in Review

Jennison Associates sold out of Eledon Pharmaceuticals (ELDN) in Q4 2014, closing a stake of 970 shares — an estimated $2.38M sold.

Jennison Associates first reported a position in ELDN in Q3 2014 and held it in 1 quarter. The position peaked at $2.38M in Q3 2014. 44 funds tracked by Wall St. Rank hold ELDN as of Q4 2014.

  • Jennison Associates reported no remaining Eledon Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Jennison Associates sold 970 Eledon Pharmaceuticals shares in Q4 2014, an estimated $2.38M.
  • Jennison Associates first reported a position in Eledon Pharmaceuticals in Q3 2014 and held it in 1 quarter.
  • Jennison Associates's Eledon Pharmaceuticals position peaked at $2.38M in Q3 2014.
  • 44 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2014.

Based on Jennison Associates's 13F filing for Q4 2014, filed 6 Feb 2015.